Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2006-09-05
2006-09-05
Wehbé, Anne M. (Department: 1633)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C435S455000, C424S093200, C424S093210
Reexamination Certificate
active
07101704
ABSTRACT:
Disclosed is a mesenchymal stem cell and/or cell of the adipocyte lineage that (i) has been modified to have at least one exogenous antigen bound to at least one primary surface molecule of said cell such that said at least one antigen can initiate an immune response and (ii) also expresses at least one co-stimulatory molecule. The antigen is preferably a protein, polypeptide, lipid or glycolipid. The primary surface molecule is MHC I, MHC II or CD1. Also disclosed is a method for stimulating presentation of at least one exogenous antigen fragment on a mesenchymal stem cell primary surface molecule by contacting a mesenchymal stem cell that is capable of expressing at least one co-stimulatory molecule with (i) an exogenous antigen or (ii) genetic material that codes for the exogenous antigen which the mesenchymal stem cell processes into at least one antigen fragment. The method can further include contacting the mesenchymal stem cell with interferon-γ. Also disclosed are a method for determining the state of activation of a T lymphocyte population and a method for the treatment or prevention of a disease in an animal.
REFERENCES:
patent: 5591625 (1997-01-01), Gerson et al.
patent: 5962320 (1999-10-01), Robinson
Bachmann et. al.; In vivo versus in vitro assays for assessment of T- and B- cell function, 1994, Current Opinion in Immunology 6: 320-326.
Yasutomi et. al.; A Vaccine-Elicited, Single Viral Epitope-Specific Cytotoxic T Lymphocyte Response . . . Virus Challenge, 1995. Journal of Virology: 2279-2284.
Ross et. al.; Gene Therapy in the United States: A Five-Year Status Report, 1996, Human Gene Therapy 7: 1781-.
Orkin et. al.; Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.
Melian et al. (1996) Current Opin. Immunol., vol. 8, 82-88.
Krampera et al. (2003) Blood, vol. 101, No. 9, 3722-3729.
Lillie Raymond J.
Olstein Elliot M.
Osiris Therapeutics, Inc.
Wehbe Anne M.
LandOfFree
Antigen presenting mesenchymal stem cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen presenting mesenchymal stem cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen presenting mesenchymal stem cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574761